FIGURE 1 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
Year: 2023
Type: other
Abstract: Statins significantly improve responses in a retrospective analysis of venetoclax clinical trials in R/R multiple myeloma. Results of patients with R/R multiple myeloma from venetoclax clinical trials receiving the standard therapy of Dex and a proteasome inhibitor (bortezomib for the phase Ib trial (NCT01794507 also known as M12-901) and carfilzomib for the ongoing phase II trial (NCT02899052 also known as M15-538) were pooled for post hoc analysis of background statin use on responses to therapy. A, Univariate analysis of the pooled trials assessing background statin use on response to therapy identified a significant difference in the proportion of subjects achieving sCR that is appreciated in each individual study (***, P < 0.001). B, No patient on statins experienced progressive disease (PD) in either individual study, resulting in a significant difference in the pooled analysis (*, P < 0.05). C, Multivariate analysis to evaluate known independent variables that affect patient outcomes, including prior lines of therapy, cytogenetic risk, and t(11;14) status in relation to statin use on patient responses. Statin use trended closer to support association with CR or better when accounting for prior lines of therapy, while t(11;14) and cytogenetic risk had no association with CR or better. No high-risk patients achieved sCR, thus cytogenetic risk was dropped from multivariate analysis of sCR. Neither prior lines of therapy nor t(11;14) status were associated with sCR, while statin use was strongly associated with increased rates of sCR (**, P < 0.01).
Authors: Dennis Juarez, Roberta Buono, Shannon M. Matulis, Vikas A. Gupta, Madeleine Duong, Jacob Yudiono, Madhuri Paul, Sharmila Mallya, Grace Diep, Peter Hsin, Alexander Lu, Sang Mi Suh, Vy M. Dong, Andrew W. Roberts, Joel D. Leverson, Muhammad Jalaluddin, Zhuangzhuang Liu, Orlando F. Bueno, Lawrence H. Boise, David A. Fruman
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4389478263